Publication Name	World Journal of Gastroenterology
Manuscript ID	42524
Country	Italy

Received	2018-09-27 06:01
Peer-Review Started	2018-09-27 06:13
To Make the First Decision	2018-10-24 02:13
Return for Revision	2018-10-26 07:48
Revised	2018-11-14 10:56
Second Decision	2018-11-16 07:41
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-11-16 18:44
Articles in Press	2018-11-16 18:44
Publication Fee Transferred
Edit the Manuscript by Language Editor	2018-11-27 01:34
Typeset the Manuscript	2018-12-20 08:31
Publish the Manuscript Online	2018-12-21 10:07

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Novel oral-targeted therapies for mucosal healing in ulcerative colitis
Manuscript Source	Invited Manuscript
All Author List	Elisabetta Antonelli, Vincenzo Villanacci and Gabrio Bassotti
ORCID	Author(s) ORCID Number Elisabetta Antonelli http://orcid.org/0000-0002-9475-9047 Vincenzo Villanacci http://orcid.org/0000-0002-6774-1060 Gabrio Bassotti http://orcid.org/0000-0002-0237-1812
Funding Agency and Grant Number
Corresponding Author	Gabrio Bassotti, MD, PhD, Associate Professor, Department of Medicine, Gastroenterology and Hepatology Section, University of Perugia Medical School, Piazza Lucio Severi, San Sisto 06156, Italy. gabassot@tin.it
Key Words	Mucosal healing; New oral treatments; Ozanimod; Peficitinib; Tofacitinib; Ulcerative colitis
Core Tip	The disease activity of ulcerative colitis (UC) is not sufficiently controlled in a subgroup of patients under the current therapeutic regimens. New oral substances are in the pipeline for treating UC. Mucosal healing (MH) has emerged as an important predictor of modifications in the natural disease course of UC. This review describes the efficacy of new oral drugs in inducing and maintaining MH in UC.
Publish Date	2018-12-21 10:07
Citation	Antonelli E, Villanacci V, Bassotti G. Novel oral-targeted therapies for mucosal healing in ulcerative colitis. World J Gastroenterol 2018; 24(47): 5322-5330
URL	https://www.wjgnet.com/1007-9327/full/v24/i47/5322.htm
DOI	https://dx.doi.org/10.3748/wjg.v24.i47.5322

Full Article (PDF)	WJG-24-5322.pdf
Full Article (Word)	WJG-24-5322.doc
Manuscript File	42524-Review.docx
Answering Reviewers	42524-Answering reviewers.pdf
Audio Core Tip	42524-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	42524-Conflict-of-interest statement.pdf
Copyright License Agreement	42524-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	42524-Language certificate.pdf
Peer-review Report	42524-Peer-review(s).pdf
Scientific Misconduct Check	42524-Scientific misconduct check.pdf
Scientific Editor Work List	42524-Scientific editor work list.pdf